Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes

Journal of Perinatology volume 27, pages 164–170 (2007)Cite this article

Abstract

Objective:

To describe the current use of treatments to prevent or treat patent ductus arteriosus (PDA) in preterm infants, examine the association between different treatment strategies and neonatal outcomes and review the variation in these practices between centers.

Study design:

Cohort study of infants born between 23 and 30 weeks gestation managed by the Pediatrix Medical Group from 1997 to 2004. We collected data on demographics, indomethacin and ligation, and outcomes of the following five groups: prophylactic indomethacin treatment: infants treated with indomethacin on day of life (DOL) 0 or 1; indicated indomethacin treatment: infants treated with indomethacin after DOL 1; PDA without treatment: infants with a PDA without report of treatment; ligation only: infants with a PDA ligation without use of indomethacin and no PDA: infants without a PDA and without treatment.

Results:

There were 6189 (18%) patients who received prophylactic indomethacin, 5690 (16%) patients received indicated treatment, 3886 (11%) patients had a PDA without treatment, 702 (2%) patients received ligation only and 18 136 (52%) patients had no PDA. In multivariate analysis, mortality among survivors to 2 days of age was lower (odds ratio (OR) 0.6, 95% confidence interval (CI) 0.5 to 0.7, P<0.01) and chronic lung disease, isolated intestinal perforation and severe retinopathy of prematurity (stages 3 and 4) were higher (OR 1.5, 95% CI 1.3 to 1.6, P<0.01; OR 1.5, 95% CI 1.1 to 2.0, P<0.01 and 1.4, 95% CI 1.2 to 1.6, P<0.01, respectively) in the indicated treatment group compared with the PDA without treatment group. The proportion of infants receiving prophylactic indomethacin among all infants and infants receiving indicated treatment among neonates with a report of a PDA varied by site from 0 to 59% (median 9.5%) and 0 to 100% (median 62%), respectively.

Conclusions:

Indomethacin use for intraventricular hemorrhage prevention and/or treatment of a PDA is common, but the selection of infants for treatment, and the decision of when and how to treat vary widely between centers. Our findings suggest the need for randomized, placebo-controlled trials of the effect of treatment of the PDA in preterm infants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Dollberg S, Lusky A, Reichman B . Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr 2005; 40 (2): 184–188.

    Article  CAS  PubMed  Google Scholar 

  2. Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O’Shea TM . Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association Pediatrics 1999; 104 (6): 1345–1350.

    CAS  PubMed  Google Scholar 

  3. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G . Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995; 126 (4): 605–610.

    Article  CAS  PubMed  Google Scholar 

  4. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344 (26): 1966–1972.

    Article  CAS  PubMed  Google Scholar 

  5. Shorter NA, Liu JY, Mooney DP, Harmon BJ . Indomethacin-associated bowel perforations: a study of possible risk factors. J Pediatr Surg 1999; 34 (3): 442–444.

    Article  CAS  PubMed  Google Scholar 

  6. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344 (2): 95–101.

    Article  CAS  PubMed  Google Scholar 

  7. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004; 114 (6): 1649–1657.

    Article  PubMed  Google Scholar 

  8. Zbar RI, Chen AH, Behrendt DM, Bell EF, Smith RJ . Incidence of vocal fold paralysis in infants undergoing ligation of patent ductus arteriosus. Ann Thorac Surg 1996; 61 (3): 814–816.

    Article  CAS  PubMed  Google Scholar 

  9. Laughon MM, Simmons MA, Bose CL . Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr 2004; 16 (2): 146–151.

    Article  PubMed  Google Scholar 

  10. Thorp JA, Jones PG, Knox E, Clark RH . Does antenatal corticosteroid therapy affect birth weight and head circumference? Obstet Gynecol 2002; 99 (1): 101–108.

    CAS  PubMed  Google Scholar 

  11. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR . Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 2006; 117 (1): 67–74.

    Article  PubMed  Google Scholar 

  12. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR . Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006; 117 (6): 1979–1987.

    Article  PubMed  Google Scholar 

  13. Narayanan M, Cooper B, Weiss H, Clyman RI . Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr 2000; 136 (3): 330–337.

    Article  CAS  PubMed  Google Scholar 

  14. Attridge JT, Clark R, Walker MW, Gordon PV . New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. J Perinatol 2006; 26 (2): 93–99.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neonatal-Perinatal Medicine, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    M Laughon & C Bose

  2. Pediatrix Medical Group, Sunrise, FL, USA

    R Clark

Authors
  1. M Laughon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Bose
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Laughon.

Additional information

There is no financial disclosure for the authors to report.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laughon, M., Bose, C. & Clark, R. Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes. J Perinatol 27, 164–170 (2007). https://doi.org/10.1038/sj.jp.7211662

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211662

Keywords

This article is cited by

Search

Advanced search

Quick links